PRESS RELEASES
Seed Therapeutics has completed construction of a new state of the art innovation and research center at 411 Swedeland Road in King of Prussia, Pennsylvania.
King of Prussia, PA – July 01, 2022 – Seed Therapeutics has completed construction of a state of the art 10,000 square foot innovation and research center including 7,000 square feet of cutting edge lab space at 411 Swedeland Road in King of Prussia, Pennsylvania.
LATEST PRESS RELEASES
SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago Two PROTAC synergy using two E3 ligases for achieving levels of degradation of...
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors King of Prussia, PA – January 28,...
Nature: Protein degraders push into novel target space
info@seedtherapeutics.com info@seedtherapeutics.com PUBLICATIONS Nature: Protein degraders push into novel target space Clinic-ready molecular glues and heterobifunctional PROTAC drugs are taking targeted protein degradation into uncharted territory.